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1. Introduction 
Human embryonic stem cells (hESCs) are promising materials for both basic and applied 
research fields such as human developmental biology and drug discovery because of their 
capacity for long-term self-renewal and differentiation into virtually all types of cells and 
tissues (Thomson et al., 1998; Hoffman & Carpenter, 2005). For example, with regard to their 
applications for drug development research, these cells can be used test whether drugs 
under development are efficacious against specific diseases by using hESCs-derived disease 
models which show disease phenotypes (Barbaric et al., 2010; Laustriat et al., 2010). 
Genetic manipulation is a useful strategy for generating cellular disease models. Random 
integration of exogenous genes into the genome of hESCs is the most straightforward and 
easiest method. Random integration, however, often results in inactivation or silencing of 
integrated genes in hESCs (Ellis, 2005; Liew et al., 2007; Xia et al., 2007) and also might alter 
the cellular phenotypes due to insertional mutagenesis, which disrupts gene functions in 
undefined gene regions (Hacein-Bey-Abina et al., 2003; Nienhuis et al., 2006). Furthermore, 
the reliability of data may be compromised by differences in the transgene integration sites 
when comparing multiple transgenic cell lines. Introducing transgenes by gene targeting is 
one way to avoid undesired gene silencing and insertional mutagenesis, but the targeting 
efficiency in hESCs is notoriously low (Zwaka and Thomson, 2003; Urbach et al, 2004; Irion 
et al, 2007; Di Domenico et al, 2008; Ruby et al, 2009). Therefore, a lot of time and effort may 
be required to obtain gene-targeted hESC clones. To address these issues, several strategies 
have been explored. Researchers have identified usable native sites for gene integration in 
the human genome. Bacteriophage phiC31 integrase, or adeno-associated virus type 2 
(AAV2), can mediate plasmid integration into pseudo-attP sites or the adeno-associated 
virus integration site 1 locus in the genome, respectively (Thyagarajan et al., 2008; Smith et 
al., 2008). However, the human genome possesses 23 different pseudo-attP sites, so the 
integration site cannot be specifically controlled, and the AAV2-mediated targeting 
efficiency is still low (4.16%). In contrast, foreign sequences such as bacterial loxP and yeast 
FRT are useful for gene integrations into the genome. Both loxP and lox2272 sequences can 
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be introduced at the silence-resistance sites of hESCs, but the selection efficiency of 
recombination-mediated cassette exchange is relatively low (two out of 92 clones) (Du et al., 
2009). As a result, it is thus considered that there is room for improvement in the targeting 
and the selection of loxP technology. 
 
 
 
 
Fig. 1. Schematic diagrams of the conventional random integration and site-directed 
integration. (A) Conventional random integration requires selection of the proper clone(s) 
from among a large number of clones. This puts a burden on researchers to scale-up, 
differentiate and check the quality of each individual clone. (B) The site-directed integration 
produces clones by manipulating the only docking site. Hence, all clones can be used. 
In this chapter, a site-directed integration system based on homologous recombination (HR) 
and Cre recombinase-mediated site-specific integration is described. First, gene targeting 
was performed to introduce a docking site containing two loxP sites and a hygromycin 
resistance gene without the first methionine codon into the hypoxanthine 
phosphoribosyltransferase 1 (HPRT) locus. Next, a gene of interest was inserted into the 
docking site by Cre recombinase. Correct insertion into the docking site confers hygromycin 
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resistance. Using this strategy, when an EGFP expression cassette (CAG promoter-driven 
EGFP) was inserted into the HPRT-docking site of the hESC line, the EGFP fluorescence was 
detected in all of the hygromycin-resistant clones. Furthermore, when a single vector 
carrying both an rtTA expression cassette and a Tetracycline (Tet) Response Element (TRE)-
driven EGFP was introduced into the docking site, doxycyclin (Dox) could induce EGFP 
expression in the hygromycin resistant clones in a dose-dependent manner, and the clones 
did not leak EGFP expression in the absence of Dox. 
Every time a transgene is inserted into the HPRT locus, carrying out conventional gene 
targeting is impractical because of the low HR efficiency, whereas the new site-directed 
integration system has greatly improved efficiency. Once the hESC lines with the docking 
site in the HPRT locus are generated by HR, any gene of interest can be integrated into the 
HPRT locus with nearly 100% efficiency. Furthermore, all clones created by this system have 
the same genetic background. This enables the effects among different genes integrated at 
the HPRT locus to be evaluated without consideration of data from multiple cell lines, 
unlike the usual need for comparison among randomly integrated hESC lines. Therefore, the 
new site-directed integration system makes it possible to produce transgenic hESC lines 
quickly and thus obtain reliable research results (Fig. 1). 
2. Site-directed integration of transgenes for hESCs and its future 
applications 
2.1 Homologous recombination for hESCs 
To integrate the docking site for site-directed gene integration, we first carried out HR for 
hESCs. We chose the HPRT locus as the transgene integration site because, along with 
ROSA26 and others, this locus is considered to always allow transgene expression in the 
mouse genome (Bronson et al., 1996; Zambrowicz et al., 1997; McCreath et al., 2000). In 
addition, previous reports have shown the success of HR to the HPRT locus of hESCs 
(Zwaka & Thomson, 2003).  
To generate the HPRT-targeting vector, the 5’- and 3’- homologous arms (7.0 kb and 2.0 kb 
respectively) were amplified from KhES-1 genomic DNA by polymerase chain reaction (PCR) 
using KOD FX (TOYOBO, Japan, also known as KOD Xtreme, supplied from Merck). This 
targeting vector contained a loxP site flanked by a neomycin resistance gene expression 
cassette, and another loxP site was located 5’ to a promoter-less hygromycin resistance gene 
lacking the start ATG codon. These elements thus became the docking site for gene integration. 
To exclude the effects of external transcription factors, the docking site was inserted between 
two DNase I-hypersensitive site 4 (HS4) insulators (Chung et al., 1993) (Fig. 2). After the 
targeting vector was linearized by cutting the NotI site at the distal end of the 5’arm, it was 
then delivered to the female hESC KhES-1 cells (Suemori et al., 2006) by electroporation. 
 
 
 
 
Fig. 2. The structure of the targeting vector for the human HPRT locus.  
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For electroporation, two confluent 100 mm dishes of KhES-1 (2-4 x 106) cells were 
completely dissociated using 0.05% trypsin and 0.2 mM EDTA. Cells were mixed with 10 g 
of linearized targeting vector, electroporated in GenePulser Xcell (BioRad) using the 
following settings: square mode, 250 V, 4 ms x 2, 5 s interval, and then dispensed into a 60 
mm dish plated with neomycin-resistant feeders (mouse embryonic fibroblasts (MEFs)). 
Two days after electroporation, the cells were treated with 50 g/ml G418 (Sigma). The next 
day, the G418 concentration was increased to 100 g/ml. Selection was performed for 10-14 
days post-electroporation. 
Out of the 424 G418-resistant clones screened, six (1.42%) had undergone the desired 
homologous recombination event (Table 1) (Sakurai et al., 2010). HR was confirmed by PCR 
and a Southern blotting analysis (Sakurai et al., 2010). One targeted clone, named K1-HS, 
was randomly selected and used for subsequent gene replacement. We also carried out gene 
targeting for KhES-1 sub-line 1 (Hasegawa et al., 2006) and this targeting efficiency was 
0.89% (three clones underwent HR out of 336 G418-resistant clones) (Table 1).  
 
 
 
Table 1. HPRT gene targeting experiments in hESCs. 
2.2 Site-directed gene integration 
To perform site-directed integration for the HPRT locus, we constructed the pInsert vector 
as a basic vector, which contained the EF1 promoter, a Kozak sequence (Kozak, 1987), an 
ATG codon and a loxP site in this order (Fig. 3A). To examine whether this site-directed 
integration system was functional, we tried to integrate an EGFP expression vector into the 
HPRT locus and constructed the pInsert-Tif-CAG-EGFP vector, which carries an EGFP 
transgene under the control of the CAG promoter and a Cor insulator, with the tandem core 
element of the chicken HS4 beta globin insulator (Otsuki et al., 2005) (Fig. 3B). 
Electroporation was used to introduce the plasmids into the cells. Five micrograms of a Cre 
expression vector (pEF1-Cre) and 20 g of the pInsert-Tif-CAG-EGFP vector were used for 
each electroporation procedure. The number of cells (K1-HS), the methods used for cell 
dissociation, and the electroporation settings were the same as those used for the gene 
targeting experiments. The ESCs were then plated onto hygromycin-resistant MEFs 
(Dainippon Sumitomo Pharma, Japan). Hygromycin selection (40 g/ml, Invitrogen) was 
started two days after electroporation, and was performed for 10-14 days post-
electroporation. 
In the presence of hygromycin, survival is highly skewed towards clones that have 
undergone the correct recombination event. This is because our method requires the 
reconstitution of the hygromycin resistance gene by Cre-mediated recombination between 
the EF1 promoter-ATG sequence in a plasmid vector carrying the transgene of interest and 
a promoter-less hygromycin resistance gene lacking a start codon in the targeted HPRT 
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Fig. 3. (A) A vector developed for site-directed integration, pInsert. (B) The strategy used for 
site-directed integration. Cre recombinase-mediated integration of the pInsert vectors 
carrying a gene of interest confers hygromycin resistance. 
locus (Fukushige & Sauer, 1992; Beard et al., 2006). In this case, only clones in which the 
CAG-EGFP cassette is integrated into the docking site on the HPRT locus can survive under 
hygromycin selection. All hygromycin resistant clones therefore theoretically express EGFP, 
because the HPRT locus supports strong, ubiquitous expression of inserted sequences, and it 
is not subject to any gene-silencing effects. 
In five transfection experiments, a total of 186 hygromycin-resistant clones were obtained, 
and all of them were EGFP-positive (Table 2) (Sakurai et al., 2010). Eight clones were 
randomly selected from the hygromycin-resistant clones, and all of them expressed similar 
levels of EGFP. The correct and single-copy integration were confirmed by PCR and a 
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Table 2. Efficiency of EGFP expression in the site-directed integration using a pInsert-Tif-
CAG-EGFP vector. 
Southern analysis (Sakurai et al., 2010). The correctly integrated clones were expected to 
have lost their neomycin resistance due to cassette exchange. As expected, all clones (80 
clones that were randomly chosen from the initial 186) were neomycin-sensitive (Sakurai et 
al., 2010). The pInsert-Tif-CAG-EGFP integrated clones maintained their expression of EGFP 
for at least 6 months in an undifferentiated state in the presence of hygromycin (data not 
shown). When these cells were differentiated into neurons, it was possible to detect EGFP 
expression in the resulting neurons (Fig. 4).  
 
 
Fig. 4. Neural differentiation of a pInsert-Tif-CAG-EGFP integrated clone. Bar = 100 m. 
2.3 Inducible gene expression based on the site-directed integration 
We attempted to introduce all components of the Tet-inducible gene expression system into 
the docking site at the HPRT locus. Site-directed integration was performed by co-
transfection of a pInsert vector carrying CAG-rtTA, the Cor insulator and TREtight-EGFP 
(pInsert-CTOR-EGFP) (Fig. 5), with a pEF1-Cre. Fifty micrograms of pInsert-CTOR-EGFP 
was used for this experiment, and the other methods were the same as were used for the 
site-directed integration of pInsert-Tif-CAG-EGFP (Sakurai et al., 2010). 
Treatment with Dox for 2 days after the emergence of hygromycin-resistant colonies 
resulted in a dose-dependent induction of EGFP expression (Sakurai et al., 2010). Two clones 
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Fig. 5. (A) pInsert-CTOR and (B) pInsert-CTOR-EGFP vectors for the first-generation Tet-
inducible gene expression system based on the site-directed integration. 
that were randomly selected exhibited similar responsiveness to Dox (Sakurai et al., 2010). 
Their correct integration of pInsert-CTOR-EGFP was confirmed by PCR and a Southern 
blotting analysis (Sakurai et al., 2010). One of the two clones was further analyzed in 
additional experiments, and it could form embryoid bodies (EBs) and retained the ability to 
differentiate into representative cells of all three germ layers (Sakurai et al., 2010). Taken 
together, these results indicate that these ESCs maintain their pluripotency after a second 
round of genetic modification and clonal selection. 
Although we put two insulators on both sides of the TRE-EGFP cassette in the pInsert-
CTOR-EGFP integrants to avoid the leaky expression of EGFP, the results indicated that the 
faint EGFP signals could still be detected in the absence of Dox (Sakurai et al., 2010). 
Furthermore, although a FACS analysis showed that most of the Dox-treated live ESCs 
expressed EGFP, the fluorescent micrographs displayed their EGFP expression in a patchy 
fashion (Sakurai et al., 2010). Therefore, we tried to improve the pInsert-CTOR vector for 
practical use. 
2.4. pInsert-Tet5 vector: the reliable Tet-on system 
We investigated methods to diminish the leaky expression of transgenes downstream of the 
TRE. We examined the orientation of the TRE-EGFP cassette and the types of insulators. We 
did not modify the CAG-rtTA cassette because its structure was the same as the CAG-EGFP 
cassette of the pInsert-Tif-CAG-EGFP vector that demonstrated a robust expression of 
EGFP. As a result, we developed a pInsert-Tet5 vector with undetectable expression of 
EGFP in the absence of Dox. 
The pInsert-Tet5 vector was generated by exchanging the Cor insulator of pInsert-CTOR for 
the HS4 insulator with orientation in opposition to the HS4 insulators of the K1-HS cells 
(Fig. 6A). The pInsret-Tet5-EGFP was introduced into K1-HS cells with pEF1-Cre, and 
transfected cells were selected by hygromycin treatment (Fig. 6B). The experimental method 
was the same as that used for the pInsert-CTOR-EGFP. After the emergence of hygromycin-
resistant cells, Dox was added for induction of EGFP expression (Fig. 7A). Unlike the 
pInsert-CTOR-EGFP integrated clones with their patchy expression, the fluorescent 
micrographs indicated that EGFP was expressed in most of the cells in the colonies in 
response to Dox treatment (Fig. 7A).  
We picked up three pInsert-Tet5-EGFP integrated clones randomly and analyzed their 
responsiveness to Dox. All three clones expressed a similar level of EGFP when they were 
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treated with Dox for 3 days (Fig. 7B). In the absence of Dox, the fluorescence intensities of all 
clones were the same as their parental K1-HS, indicating that the pInsert-Tet5-EGFP 
integrants do not leak any significant level of EGFP expression in the absence of Dox (Fig. 
7B). Moreover, we further analyzed clone 3, and could induce EGFP expression in a Dox 
dose-dependent manner (Fig. 7C). Single-copy integration of a pInsert-Tet5-EGFP vector 
was confirmed by a Southern analysis (Fig. 7D). 
 
 
 
 
Fig. 6. (A) The pInsret-Tet5 vector used to generate a reliable Tet-On system. The insulator 
of this vector (HS4) was changed from that of the pInsert-CTOR vector (Cor). (B) The 
strategy for site-directed integration of pInsert-Tet5-EGFP. The TRE-EGFP cassettes are 
wedged between two HS4 insulators to avoid the leaky expression of EGFP. 
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Fig. 7. (A) Dox-inducible EGFP induction of a pInsert-Tet5-EGFP integrated hygromycin-
resistant clone. (B) The FACS analysis of three pInsert-Tet5-EGFP integrated clones. All of 
them expressed a similar level of EGFP when they were treated with 2 g/ml of Dox for 3 
days. Furthermore, the pInsert-Tet5-EGFP integrants did not leak any detectable EGFP in the 
absence of Dox. (C) The dose-dependent induction of EGFP expression by Dox. Cells were 
treated with 100, 250, 500, 1000 or 2000 ng/ml Dox for 3 days. (D) The Southern blotting 
analysis. Genomic DNA was digested by EcoRV and hybridized with an EGFP probe. M: Size 
marker, 3: Clone 3, N: Non-integrated genome. The expected band size was 7.5 kb.  
We believe that the combination of K1-HS and pInsert-Tet5 is a feasible Dox-inducible gene 
expression system. To establish even greater feasibility for using this system, we plan to 
examine to accuracy of the transgene integration, Dox responsiveness in differentiated cells, 
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epigenetic modification near the docking site, and genomic structure of pInsert-Tet5 
integrated locus. There is a possibility that several copies of the pInsert vector may insert in 
tandem into the docking site in the site-directed integration system. In the case of pInsert-
Tet5, tandem integration of pInsert-Tet5 vectors may abolish the reliable regulation by Dox, 
because the gene of interest would be downstream of the EF1 promoter, without 
intervening insulators. Therefore, it will be necessary to pick up a few hygromycin-resistant 
clones and to confirm their correct integration of the pInsert-Tet5 vector. 
2.5 Future applications of the site-directed integration system in human pluripotent 
stem cells 
The drug discovery and development process is time-consuming and costly. Nevertheless, 
the average success rate of approval is approximately 11% after clinical trials (Kola and 
Landis, 2004). The major causes of failure are a lack of efficacy and toxicity in humans (Kola 
and Landis, 2004). Animal disease models can provide a wealth of information about the 
complexity of various disease processes, but efficacious lead compounds for these models 
are often found to be inefficacious during human clinical trials (Kola and Landis, 2004). 
Moreover, animal models do not always indicate the toxicity of compounds in humans 
because of the differences in the biological processes in humans and animals (Martignoni et 
al., 2006). These facts demonstrate the need for more predictive drug screening systems 
(Kola and Landis, 2004; Ebert and Svendsen, 2010). In this regard, human pluripotent stem 
cells are considered to be a promising cell source for drug screening because of the virtually 
limitless supply of normal human cells that can be differentiated into any specific cell type. 
2.5.1 Disease modeling and efficacy screening 
There are several approaches that have been designed to create in vitro disease models using 
pluripotent stem cells. One is that ESCs carrying serious genetic disorders can be 
differentiated into cells with disease-related phenotypes. Preimplantation genetic diagnosis 
(PGD) can identify embryos with genetic defects. The generation of disease-specific hESC 
lines via PGD has already been reported. For example, there are hESC lines with cystic 
fibrosis, myotonic dystrophy type I, Huntington’s disease, adrenoleukodystrophy, 
Dushenne muscular dystrophy, Becker muscular dystrophy, fragile-X syndrome and 
thalassaemia (Pickering et al., 2005; Verlinsky et al., 2005; Mateizel et al., 2006; Stephenson et 
al., 2009). Differentiation of these disease-specific hESC lines into each of the specific cell 
types that manifest disease phenotypes may make it possible to screen for factors that 
restore the normal phenotype and to identify factors associated with disease initiation or 
progression. Furthermore, many induced pluripotent stem cells (iPSCs) have been generated 
from adult patients with incurable diseases and it is also hoped that they will provide new 
sources for drug screening (Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Lee et al., 
2009; Soldner et al., 2009; Ye et al., 2009; Maehr et al., 2009; Ye et al., 2009). 
Using pluripotent stem cells carrying disease-linked genes and a high-throughput screening 
system, small-molecule compounds or humoral factors can be identified as potential 
therapeutic drugs (Barbaric et al., 2010). However, in order to more effectively screen for 
intracellular proteins or artificial peptides that are involved in or affect the disease process, 
the site-directed integration system may be more useful. In this section, we describe an 
example of an application of the site-directed integration system for drug screening and 
disease mechanism research. 
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First, as shown in Fig. 8, the docking site was targeted to the HPRT locus of diseased ES/iPS 
cells. Although the targeting efficiency of the docking site by electroporation is relatively 
low (Table 1), more efficient gene targeting method for human ESC/iPS cells using helper-
dependent adenoviral vectors or zinc-finger nuclease has recently been reported (Suzuki et 
al., 2008; Lombardo et al., 2007; Zou et al., 2009) and applying these targeting methods may 
resolve these technical problems. Next, libraries of pInsert vectors which contain expression 
cassettes of cDNAs coding for various proteins or artificial peptides are constructed. 
Insertion of each pInsert vector into the targeted docking site confers stable expression of 
exogenous proteins in the diseased ES/iPS cells. These ES/iPS cells should show the 
phenotypes of the disease after differentiation. However, if differentiated cells show normal 
phenotypes, this means that the disease phenotype has been resolved, suggesting that 
expressing the specific exogenous protein influences the disease process. Such exogenous 
proteins can be identified by analyzing the sequence of the integrated pInsert vector.  
 
 
 
Fig. 8. A schematic diagram for discovering potential disease-curing proteins or peptides 
using pInsert vector libraries and disease-specific ES/iPS cells. 
However, although a number of disease-specific ES/iPS cell lines have been established, 
only a few studies have demonstrated that the differentiated cells showed disease 
phenotypes (Ebert et al., 2009; Lee et al., 2009), while many disease-specific ES/iPS cells did 
not show any disease phenotypes, perhaps because of the late onset or multi-factorial nature 
of such diseases. Therefore, long-term culture might be needed before the disease 
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phenotypes will emerge or the disease will be initiated. However, overexpression of disease-
linked genes in K1-HS cells using the site-directed integration system might enable an 
accelerated onset of disease phenotypes, and if overexpression of the disease-related gene 
leads to cell death, the pInsert-Tet5 vector system represents a suitable method because it 
can control gene expression by Dox, allowing for short-term gene expression. 
2.5.2 Toxicity screening 
Toxicity screening may be the most advanced application of pluripotent stem cells for drug 
screening. Public-private collaborations such as Stem Cells for Safer Medicine or Stem Cells 
and Drug Discovery Institute have been launched to enable consistent differentiation of 
stem cells into particular cell types with physiologically relevant phenotypes suitable for 
toxicology testing. Cardiomyocytes derived from human ES/iPS cells have already begun to 
be used for drug-induced cardiotoxicity screening (Asai et al., 2010). 
In the drug development process, it is necessary to evaluate the metabolism of the novel 
compound in hepatocytes, because the liver is the main detoxification organ in the body. 
The models used at present are primary hepatocytes or immortalized cell lines such as 
HepG2, which present major limitations in terms of supply and their relevance to normal 
metabolic reactions, respectively (Wilkening et al., 2003; Laustriat et al., 2010). Recently, 
Inamura et al. reported the efficient generation of hepatoblasts from human pluripotent 
stem cells (Inamura et al., 2011). However, it is still difficult to obtain homogeneous 
populations of mature hepatocytes, and contamination with other unwanted cell types 
decreases the reliability of the toxicity data. Using a pInsert vector equipped with a lineage-
specific selection marker and an HS4 insulator downstream of loxP may enable the 
reproducible production of concentrated hepatocytes. 
2.5.3 Applications for cellular medicine 
Human pluripotent stem cells are expected to provide sources for cellular therapy as well as 
drug screening. Geron Corporation already started a phase I clinical trial of transplantation 
of oligodendrocyte progenitor cells derived from hESCs to patients with spinal cord injury 
(http://www.geron.com/GRNOPC1Trial/). However, when transplanting differentiated 
cells from human ES/iPS cells, it is necessary to consider the potential for uncontrollable 
overproliferation and tumor formation due to implantation of small numbers of 
undifferentiated cells. Using the pInsert-Tet5-like vector equipped with an undifferentiated 
state-specific promoter instead of the CAG promoter and a proper suicide gene downstream 
of TRE may resolve this problem (Fig. 9). Because the undifferentiated cells will die in the 
presence of Dox, administration of Dox to transplant recipients can remove the 
undifferentiated cells. 
When differentiated cells are provided for cellular therapy, it is important to determine how 
to differentiate the hES/iPS cells efficiently into a single type of cells. If differentiation 
promoting factors are identified, they could be useful in the production of hES/iPS cell-
derived differentiated cells. However, there have been only a few studies using high-
throughput screening methods to discover small molecules that increase the differentiation 
of hES/iPS cells into specific cell lineages (Borowiak et al., 2009; Zhu et al., 2009). Our 
pInsert-Tet5 vector can also identify proteins with activities promoting differentiation. First, 
pInsert-Tet5 libraries which are equipped with a variety of cDNAs downstream of TRE can 
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be introduced into K1-HS cells. Hygromycin-resistant clones can then be induced to desired 
differentiation lineages, and then Dox can be added at various stages of differentiation. 
Differentiation-promoting factors at the different stages can then be identified by 
sequencing the cDNAs from clones whose differentiation efficiency has been increased by 
the administration of Dox.  
 
 
Fig. 9. A theoretic method to remove any remaining undifferentiated cells after 
transplantation using the inducible gene expression system based on the pInsert vector. 
3. Conclusion 
We have performed gene targeting in hESCs to introduce a transgene docking site into the 
HPRT locus, and have demonstrated high efficiency Cre-mediated integration of a given 
construct into this docking site. Moreover, we have developed a Tet-On system with 
undetectable background expression based on this site-directed integration. This review also 
discussed the potential applications of our site-directed integration system for drug 
discovery, toxicity screening and cell-based therapy. 
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